Blinded Diagnostics Expands Same Day Lab Testing in US and into Europe

Saddle Brook, NJ, September 5, 2014: Blinded Diagnostics today announced the expansion of business development efforts in the US and Europe. Leading the effort to provide point of care diagnostics consulting services to pharmaceutical clients will be Keren Sookne, VP of Business Development in Los Angeles, CA and Paul Gilbert, VP of Business Development in Dublin, Ireland.

Ms. Sookne, who will be responsible for the US West Coast, has a technical background with engineering and compliance experience from 4 years in biopharmaceutical manufacturing at Baxter. She holds a BS in Chemical Engineering from the University of California – Santa Barbara.

Mr. Gilbert, who will be responsible for Europe and the Middle East, is a seasoned professional with over 20 years focused in product development, medical manufacturing and clinical trial management. Paul has a BS in Organic Chemistry from The University of Wolverhampton.
"Today, we have added two skilled and experienced professionals to our team to support the growing interest in same day lab testing among pharmaceutical sponsors" said Steve Karuppan, CEO of Blinded Diagnostics. He added that "Keren and Paul are both dedicated to helping our clients identify effective testing applications for complex global clinical trials."

About Blinded Diagnostics
A pioneering contract service organization specializing in sourcing and supporting point of care diagnostic test platforms that provide same day lab test results for pharmaceutical clinical trials. Blinded Diagnostics has a successful track record of expertise in meeting large pharmaceutical company testing needs with thorough knowledge of the protocol design, Investigator training and firmware encryption. As an innovator with partners in point-of-care diagnostics, Blinded Diagnostics is at the forefront of a paradigm shift that brings flexibility and efficiency for trial sponsors. www.blindeddiagnostics.com

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.